What is the recommended dose of atropine (anticholinergic medication) for treating bradycardia in cardiac arrest?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Atropine Dosing in Cardiac Arrest

For bradyasystolic cardiac arrest, administer atropine 1 mg IV, repeated every 3-5 minutes if asystole persists, up to a maximum total dose of 2.5 mg over 2.5 hours. 1, 2

Specific Dosing by Clinical Context

Cardiac Arrest (Asystole/Bradyasystolic Arrest)

  • Initial dose: 1 mg IV 1, 2
  • Repeat: Every 3-5 minutes if asystole persists 1, 2
  • Maximum total dose: 2.5 mg over 2.5 hours 1
  • Peak action occurs within 3 minutes of IV administration 1

Symptomatic Bradycardia (Non-Arrest)

  • Initial dose: 0.5-1 mg IV 1, 3, 2
  • Repeat: Every 3-5 minutes as needed 3
  • Maximum total dose: 3 mg (complete vagal blockade) 1, 3
  • For bradycardia without cardiac arrest, the recommended dose is 0.5 mg IV repeated every 5 minutes to a total of no more than 2 mg 1

Critical Dosing Considerations

Minimum Dose Warning

Never administer atropine doses less than 0.5 mg in adults, as this can cause paradoxical bradycardia. 1, 3 This paradoxical effect results from either central reflex stimulation of the vagus or peripheral parasympathomimetic effects on the heart 1

When Atropine May Be Ineffective or Harmful

  • Type II second-degree or third-degree AV block with wide QRS complex: Atropine is likely ineffective because the block occurs in non-nodal (infranodal) tissue 3, 4
  • Heart transplant patients: Atropine may cause paradoxical high-degree AV block or sinus arrest in 20% of cases due to lack of parasympathetic reinnervation 1, 3
  • Infranodal heart blocks: Patients with blocks at the His-Purkinje level are at increased risk of adverse events, including ventricular standstill 4

Coronary Artery Disease Patients

  • Limit total atropine dose to 0.03-0.04 mg/kg in patients with coronary artery disease 2
  • The resulting sinus tachycardia may increase myocardial ischemia or infarct size 1, 3

Algorithm for Bradyasystolic Cardiac Arrest

  1. Confirm asystole in at least two ECG leads (fine ventricular fibrillation may mimic asystole) 1
  2. Administer atropine 1 mg IV immediately 1, 2
  3. Continue CPR while awaiting response (peak effect within 3 minutes) 1
  4. If asystole persists after 3-5 minutes, repeat 1 mg IV 1, 2
  5. Do not exceed 2.5 mg total dose over 2.5 hours 1
  6. If no response after maximum atropine, escalate to epinephrine and consider other reversible causes 3

Important Clinical Pitfalls

Adverse Effects to Monitor

  • Sinus tachycardia (may worsen ischemia) 1
  • Ventricular tachycardia or fibrillation (rare but reported) 1
  • Central anticholinergic syndrome with excessive doses (>3 mg): confusion, hallucinations, fever 1, 3
  • Paradoxical bradycardia with doses <0.5 mg 1

Route of Administration

  • IV route is strongly preferred 1, 2
  • Non-IV routes may result in paradoxical bradycardia 1
  • Endotracheal administration is possible but requires higher doses 5

Evidence Quality Note

The recommendation for 1 mg dosing in cardiac arrest comes from established ACC/AHA guidelines 1 and FDA labeling 2, though research evidence shows limited efficacy of atropine in bradyasystolic arrest 6. One animal study even suggested atropine may accelerate cardiac arrest in hypoxic bradycardia 7. However, given minimal harm and guideline support, the 1 mg dose remains standard practice for asystole 1, 2.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Symptomatic Bradycardia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.